Fermi Therapeutics Launches $350 Million Note Offering to Fund Clinical Programs
FRMI•Fermi Therapeutics announced a $350 million note offering to institutional investors to bolster its balance sheet. Net proceeds will fund clinical-stage programs and general corporate purposes.
1. Fermi Announces $350 Million Note Offering
Fermi Therapeutics announced a public offering of $350 million of notes to institutional investors on July 10. The transaction will generate gross proceeds before expenses, strengthening the company’s liquidity position.
2. Proceeds to Support Clinical and Corporate Programs
Net proceeds from the offering are earmarked for advancing Fermi’s clinical-stage drug candidates and covering general corporate expenses. The debt issuance enhances financial flexibility but increases total debt obligations on the balance sheet.
